Stryker Corporation

Current directors and officers who also hold a role at another S&P 500 company.

• Kevin LoboGEHC · DirectorPH · Director
• Andrew K. SilvernailIP · CEO
• Sherilyn S. McCoyKMB · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Oct 6, 2026

   Stryker Corporation (the “Company”) announced on October 6, 2026 that Kevin A. Lobo will resign from his role as Chief Executive Officer (“CEO”) of the Company on December 31, 2026 and transition to the role of Executive Chair of the Board of Directors of the Company (the “Board”), effective January 1, 2027 (the “CEO Transition”) and that Spencer S. Stiles, who currently serves as President and Chief Operating Officer of the Company, has been appointed CEO of the Company, effective January 1, 2027. In connection with Mr. Stiles’s appointment as CEO, the Board also increased the size of the Board from 10 to 11 and appointed Mr. Stiles to serve as a member of the Board, effective January 1, 2027. Mr. Stiles has not been appointed to any committee of the Board at this time. There are no arrangements or understandings between Mr. Stiles and any other person pursuant to which Mr.

   Read the 8-K filing
2. May 20, 2026

   Stryker Corporation (the “Company”) announced on May 20, 2026 that William E. Berry, Jr. has decided to retire from his role as Vice President, Chief Accounting Officer of the Company effective September 1, 2026 and that Emily Baculik, who currently serves as Vice President, Corporate Controller, will also serve as chief accounting officer of the Company effective September 1, 2026. There are no arrangements or understandings between Ms. Baculik and any person pursuant to which Ms. Baculik was selected as an officer, and no family relationships exist between Ms. Baculik and any director or executive officer of the Company. Ms. Baculik is not a party to any transaction to which the Company is or was a participant and in which Ms. Baculik has a direct or indirect material interest subject to disclosure under Item 404(a) of Regulation S-K. Biographical Information Ms.

   Read the 8-K filing
3. Dec 4, 2025

   Stryker Corporation (the “Company”) announced on December 4, 2025 that Spencer Stiles, who currently serves as Group President, Orthopaedics, has been appointed President and Chief Operating Officer of the Company effective January 1, 2026. Dylan Crotty, who currently serves as President, Instruments, has been promoted to succeed Mr. Stiles as Group President, Orthopaedics effective January 1, 2026. There are no arrangements or understandings between Mr. Stiles or Mr. Crotty and any person pursuant to which Mr. Stiles or Mr. Crotty were selected as an officer, and no family relationships exist between Mr. Stiles nor Mr. Crotty and any director or executive officer of the Company. Neither Mr. Stiles nor Mr. Crotty is a party to any transaction to which the Company is or was a participant and in which Mr. Stiles or Mr.

   Read the 8-K filing
4. May 13, 2025

   At the Annual Meeting of Shareholders of Stryker Corporation (the “Company”) held on May 8, 2025 (the “Annual Meeting”), shareholders approved the 2011 Long-Term Incentive Plan, as Amended and Restated, the 2011 Performance Incentive Award Plan, as Amended and Restated and the 2008 Employee Stock Purchase Plan, as Amended and Restated (collectively, the “Plans”), in each case, to approve an increase to the number of shares available for issuance pursuant to awards made under the Plans and to extend the duration of the Plans, among other things. Based on management’s recommendation, the Board of Directors of the Company approved the Plans in March 2025, subject to shareholder approval at the Annual Meeting. Having obtained the requisite shareholder approval for the Plans at the Annual Meeting, the Plans became effective, as amended and restated, on May 8, 2025.

   Read the 8-K filing
5. Feb 10, 2025

   On February 4, 2025, Allan Golston, a member of the Board of Directors (the “Board”) of Stryker Corporation (the “Company”), informed the Company that he will retire from the Board effective as of the Company’s annual meeting of shareholders expected to be held on May 8, 2025 (the “Annual Meeting”). Mr. Golston will continue to serve as a director until the Annual Meeting. Mr. Golston’s decision did not involve any disagreement with the Company.

   Read the 8-K filing
6. Jan 28, 2025

   Stryker Corporation (the “Company”) announced on January 28, 2025 that Glenn S. Boehnlein has decided to retire from his role as Vice President, Chief Financial Officer of the Company effective April 1, 2025 and that Preston W. Wells, who currently serves as Vice President, Group Chief Financial Officer for Orthopaedics, has been promoted to Vice President, Chief Financial Officer of the Company effective April 1, 2025. There are no arrangements or understandings between Mr. Wells and any person pursuant to which Mr. Wells was selected as an officer, and no family relationships exist between Mr. Wells and any director or executive officer of the Company. Mr. Wells is not a party to any transaction to which the Company is or was a participant and in which Mr. Wells has a direct or indirect material interest subject to disclosure under Item 404(a) of Regulation S-K.

   Read the 8-K filing
7. Dec 8, 2023

   On December 4, 2023, Dr. Srikant Datar, a member of the Board of Directors (the “Board”) of the Company, informed the Company that he will retire from the Board effective as of the Company’s annual meeting of shareholders expected to be held on May 9, 2024 (the “Annual Meeting”). Dr. Datar will continue to serve as a director until the Annual Meeting. Dr. Datar’s decision did not involve any disagreement with the Company.

   Read the 8-K filing
8. Aug 18, 2021

   On August 18, 2021, Stryker Corporation (the “Company”) announced that Timothy J. Scannell, President and Chief Operating Officer of the Company, has notified the Company of his intent to retire on March 31, 2023. Effective October 1, 2021, Mr. Scannell will transition from his current role of President and Chief Operating Officer to the position of Advisor to the Chief Executive Officer of the Company. Effective October 1, 2021, J. Andrew Pierce, Group President, MedSurg and Neurotechnology and Spencer S. Stiles, Group President, Orthopedics and Spine will together assume Mr. Scannell’s current responsibilities and report directly to the Chief Executive Officer of the Company. Messrs. Pierce and Stiles will both continue to serve on the Stryker Leadership Team. Effective October 1, 2021, Kevin A.

   Read the 8-K filing
9. Feb 5, 2021

   On February 2, 2021, Roch Doliveux, DVM, a member of the Board of Directors (the “Board”) of Stryker Corporation (the “Company”), informed the Company that he will retire from the Board effective as of the Company’s annual shareholders meeting expected to be held on May 5, 2021 (the “Annual Meeting”). Dr. Doliveux will continue to serve as a director until the Annual Meeting. Dr. Doliveux’s decision did not involve any disagreement with the Company.

   Read the 8-K filing
10. Nov 9, 2020

    On November 4, 2020, the Board of Directors of Stryker Corporation (the “Company”) increased the number of authorized directors from 10 to 11 and elected Giovanni Caforio, M.D. to fill the resulting vacancy. Dr. Caforio’s election will become effective on December 1, 2020, and he has not been appointed to any committee of the Board at this time. Dr. Caforio has been CEO of Bristol Myers Squibb (“BMS”) since May 2015 and assumed the role of Chairman of the BMS Board in May 2017. As CEO, Dr. Caforio has led BMS’s focus on researching and developing transformational medicines, which includes leading portfolios in oncology, hematology, immunology and cardiovascular disease. In 2019, he oversaw BMS’s acquisition of Celgene. Dr. Caforio joined BMS in 2000 and, with his background as a physician, has helped to strengthen BMS’s patient-focused culture.

    Read the 8-K filing
11. Apr 27, 2020

    Effective as of May 1, 2020, Stryker Corporation’s Board of Directors (the "Board") approved a temporary reduction in the base salary of the company's Chief Executive Officer, and the Compensation Committee of the Board (the "Committee") approved temporary reductions in the base salaries of the company's other named executive officers in response to ongoing uncertainty surrounding the scope and duration of the COVID-19 pandemic. Kevin Lobo, Stryker's Chief Executive Officer, will receive a 50% reduction in base salary, and the other named executive officers will receive between a 20% to 30% reduction in base salary, in each case until such time as the Board or the Committee, as appropriate, may determine in its discretion.

    Read the 8-K filing
12. Dec 5, 2019

    On November 29, 2019 , Ms. Louise L. Francesconi, a member of the Board of Directors (the “Board”) of Stryker Corporation (the “Company”), informed the Company that she plans to retire as a director and will not stand for re‑election to the Board at the Company’s annual shareholders meeting expected to be held on May 5, 2020 (the “Annual Meeting”). Ms. Francesconi will continue to serve as a director until the Annual Meeting. Ms. Francesconi’s decision to not stand for re-election did not involve any disagreement with the Company.

    Read the 8-K filing
13. Mar 27, 2019

    On March 25, 2019, Stryker Corporation (the "Company") and Michael D. Hutchinson agreed that, effective as of April 22, 2019, Mr. Hutchinson will transition from his current role of Vice President, Chief Legal Officer to the position of Vice President and Advisor to the Chairman and Chief Executive Officer of the Company. The Company has announced that Robert Fletcher will be joining the Company as Vice President, Chief Legal Officer effective April 22, 2019. On March 25, 2019, Mr. Hutchinson entered into a Transition and Retention Agreement with the Company pursuant to which he will be employed as Vice President and Advisor to the Company's Chairman and CEO from April 22, 2019 through May 31, 2020. Under the terms of the agreement, Mr. Hutchinson will continue to receive base salary at his current annual rate through May 31, 2020 or when Mr.

    Read the 8-K filing
14. Jul 10, 2018

    Stryker Corporation (the “Company”) announced on July 10, 2018 that David K. Floyd has notified the Company of his intent to retire from his role as Group President, Orthopaedics effective August 1, 2018, and that Timothy J. Scannell, who currently serves as Group President, MedSurg and Neurotechnology, will be appointed President and Chief Operating Officer effective August 1, 2018. Mr. Floyd has entered into a letter agreement with the Company pursuant to which he will continue to be employed as Group President and Advisor to the Company’s Chief Executive Officer from August 1, 2018 through June 30, 2019 to ensure a smooth transition. Under the terms of the letter agreement, Mr. Floyd will continue to receive a base salary at his current annual rate and will be eligible for an incentive bonus opportunity. Mr.

    Read the 8-K filing
15. Apr 3, 2018

    Lonny J. Carpenter notified Stryker Corporation (the “Company”) on April 2, 2018, of his intention to retire from his role as Group President, Global Quality and Business Operations effective April 30, 2018. The Company has announced that Viju Menon will be joining the Company as Group President, Global Quality and Business Operations effective April 30, 2018. Mr. Carpenter has entered into a letter agreement with the Company pursuant to which he will continue to be employed as Group President and Advisor to the Company’s Chief Executive Officer from April 30, 2018 through March 31, 2019 to ensure a smooth transition. Under the terms of the letter agreement, Mr. Carpenter will continue to receive base salary at his current annual rate and will be eligible for an incentive bonus opportunity. The summary description of the letter agreement with Mr.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.